Tumor Responses to Immunotherapy

Article 1

TUMOR RESPONSES TO IMMUNOTHERAPY

Response Evaluation Criteria in Solid Tumors (RECIST) was developed at the turn of the millennium to provide simplified and standardized response definitions. Researchers rely on these response criteria when assessing the impact of novel agents in the treatment of cancer—from conventional chemotherapies to targeted therapies.

However, immunotherapies have a very different mechanism of action compared with traditional cytotoxic anticancer agents, which is associated with different patterns of response that are not adequately described by the existing criteria.

Clinical responses to cytotoxic treatments such as chemotherapy, radiation therapy, and some targeted agents usually occur quickly (within weeks to months), because their mechanism of action involves a direct effect on tumor cells. Immunotherapies require time to induce an immune response, and they sometimes take longer to show an effect compared to cytotoxic or targeted therapies. Rather than direct cytotoxic activity on tumor cells, immunotherapies may sometimes have a delayed mechanism of action, driving the expansion of T cells, which then infiltrate the tumor and kill tumor cells.